Calcitonin in osteoporosis

Bone

Volumn 30, Issue 5 SUPPL. 1, 2002, Pages 65-66

  Kanis, J A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; LONG TERM CARE; OSTEOPOROSIS; RISK FACTOR; VERTEBRA FRACTURE;

EID: 0036241190     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00712-3     Document Type: Conference Paper

References (8)

1. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
2. Calcitonin versus etidronate in the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials
3. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD?
4. Acute and long-term increase in fracture risk after hospitalisation for vertebral fracture
5. Effect of calcitonin on vertebral and other fractures
6. Evidence for the efficacy of drugs affecting bone metabolism in the prevention of hip fracture
7. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
8. Patients with prior fractures have an increased risk of future fractures. A summary of the literature and statistical synthesis